CORRECTION

Correction to: Adverse event management in the TOURMALINE-MM3study of post-transplant ixazomib maintenance in multiple myeloma

Martin Kaiser1,2 & Meral Beksaç3 & Nina Gulbrandsen4& Fredrik Schjesvold4

& Roman Hájek5 & Philippe Moreau6&

Felipe de Arriba de la Fuente7 & María-Victoria Mateos8 & Sharon West1 & Andrew Spencer9 & S. Vincent Rajkumar10 &

Kaveri Suryanarayan11& Michael Czorniak11 & Cong Li11 & Zhaoyang Teng11

& Richard Labotka11 &

Meletios A. Dimopoulos12

# Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: Annals of Hematologyhttps://doi.org/10.1007/s00277-020-04149-5

Low-resolution figures were inadvertently created during pro-duction and published. These have been replaced with thehigh-resolution figures that were originally provided by theauthors. No changes have been made to the data presentedwithin the figures or to any other manuscript content.

Please see below for the high-resolution figures:

The online version of the original article can be found at https://doi.org/10.1007/s00277-020-04149-5

* Martin KaiserMartin.Kaiser@icr.ac.uk

1 Department of Haematology, The Royal Marsden Hospital,London, UK

2 Division of Molecular Pathology, The Institute of Cancer Research(ICR) and The Royal Marsden Hospital, 123 Old Brompton Road,London SW7 3RP, UK

3 Department of Hematology, Ankara University, Ankara, Turkey4 Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen

Center for B Cell Malignancies, University of Oslo, Oslo, Norway5 Department of Hematooncology, University Hospital Ostrava,

Ostrava, Czech Republic6 Department of Hematology, University Hospital Hôtel-Dieu,

Nantes, France

7 Servicio deHematología y OncologíaMédica, Hospital UniversitarioMorales Meseguer y Centro Regional de Hemodonación,IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain

8 Department of Hematology, University Hospital of Salamanca, CIC,IBM CC, Salamanca, Spain

9 Malignant Haematology and Stem Cell Transplantation Service,Alfred Health-Monash University, Melbourne, Australia

10 Division of Hematology, Department of Internal Medicine, MayoClinic, Rochester, MN, USA

11 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary ofTakeda Pharmaceutical Company Limited, Cambridge, MA, USA

12 Hematology and Medical Oncology, Department of ClinicalTherapeutics, School of Medicine, National and KapodistrianUniversity of Athens, Athens, Greece

https://doi.org/10.1007/s00277-020-04302-0

Published online: 27 October 2020

Annals of Hematology (2021) 100:297–302

Fig. 1 CONSORT diagram.Reproduced with permissionfrom Dimopoulos MA, Gay F,Schjesvold F et al. Oral ixazomibmaintenance followingautologous stem celltransplantation (TOURMALINE-MM3): a double-blind,randomised, placebo-controlledphase 3 trial. Lancet2019;393:253–264

298 Ann Hematol (2021) 100:297–302

Months from date of first dose

0

2

4

6

8

10

12

14

16

18

20

0 5 10 15 20

Cum

ulat

ive

incid

ence

Placebo: All gradesPlacebo: Grade 3 or 4

Ixazomib: All gradesIxazomib: Grade 3 or 4

a

Total events

0

Frequency

No ac n takenDose held

Dose delayedDose reduced

Concomitant medica on administeredDose discon nued permanently

Dose increasedDose interrupted

Concomitant procedure performedDiscon nued from study

9242

2121

127

21000

25 50 75 0 25 50 75

84

03

0200000Ixazomib Placebo

c

160

Med

ian

plat

elet

resu

lt (1

09 /L)

170

180

190

200

210

220

386251

370242

354230

354231

349228

335217

340214

328205

321204

303196

291191

285185

282180

273181

268169

259165

251147

238142

239142

224135

232133

224126

216118

206112

193111

173104

361242

IxazomibPlacebo

SE

Visit

C25D1C2D1

C3D1C4D1

C5D1C6D1

C7D1C8D1

C9D1C10D1

C11D1C12D1

C13D1C14D1

C15D1C16D1

C17D1C18D1

C19D1C20D1

C21D1C22D1

C23D1C24D1

C26D1EOT

b

Fig. 2 Cumulative incidence ofnew-onset thrombocytopenia (a)and median platelet counts (b)over time in the ixazomib andplacebo groups, and actions takenfor events of thrombocytopenia(c). Note: More than one actioncould be taken for a single eventof thrombocytopenia

299Ann Hematol (2021) 100:297–302

Incid

ence

rate

(p

erpe

rson

*cyc

le)

IxazomibPlacebo

0

5Cycle

10 15 20 25

0.02

0.04

0.06

0.08

0.10

0.12

0.14

a

Incidence, n (%)Ixazomib (n=394)

Placebo (n=259)

0–3 months 73 (19) 16 (6)>3–6 months 28 (7) 12 (5)>6–9 months 15 (4) 6 (2)>9–12 months 15 (4) 4 (2)>12–15 months 10 (3) 2 (<1)

>15–18 months 2 (<1) 0

>18–21 months 7 (2) 0>21 months 4 (1) 0

Cum

ulat

ive

incid

ence

Ixazomib: All gradesPlacebo: All grades

00

Months from date of first dose5 10 15 20 25

4

8

12

16

20

24

28

32

36

40b

Fig. 3 Incidence rate by cycle (a) and cumulative incidence (b) of new-onset nausea. Only one patient in the ixazomib arm (< 1%) and nopatients in the placebo arm had grade ≥3 nausea. Incidence rate is the

number of events in a cycle divided by the sum of patient cycles at risk ina cycle. A patient with an ongoing AE could not be at risk of getting thesame AE until it was resolved

300 Ann Hematol (2021) 100:297–302

0

5Cycle

10 15 20 25

0.010.020.03

0.050.06

0.08

0.100.09

0.07

0.04

Incid

ence

rate

(p

erpa

tient

*cyc

le)

IxazomibPlacebo

a

Incidence, n (%)Ixazomib (n=394)

Placebo (n=259)

0–3 months 43 (11) 12 (5)>3–6 months 23 (6) 2 (<1)>6–9 months 8 (2) 4 (2)>9–12 months 15 (4) 4 (2)>12–15 months 5 (1) 4 (2)>15–18 months 5 (1) 0>18–21 months 4 (1) 2 (<1)>21 months 3 (<1) 0

Months from date of first dose25

00 5 10 15 20

369

12151821242730

Cum

ulat

ive

incid

ence

Ixazomib: All gradesIxazomib: Grade 3 or 4Placebo: All grades

b

Fig. 4 Incidence rate by cycle (a)and cumulative incidence (b) ofnew-onset vomiting. No patientsin the placebo arm had grade ≥ 3vomiting. Incidence rate is thenumber of events in a cycledivided by the sum of patientcycles at risk in a cycle. A patientwith an ongoing AE could not beat risk of getting the same AEuntil it was resolved

301Ann Hematol (2021) 100:297–302

Publisher’s note Springer Nature remains neutral with regard to jurisdic-tional claims in published maps and institutional affiliations.

Ixazomib

Placebo

0

5Cycle

Incid

ence

rate

(p

er p

erso

n*cy

cle)

10 15 20 25

0.01

0.02

0.03

0.05

0.06

0.08

0.10

0.09

0.07

0.04

a

00

Months from date of first dose

Cum

ulat

ive

incid

ence

5 10 15 20 25

4

8

12

16

20

24

28

32

36

40

Ixazomib: All Grades

Placebo: All GradesIxazomib: Grade 3 or 4

Placebo: Grade 3 or 4

Incidence, n (%) Ixazomib (n=394)

Placebo (n=259)

0–3 months 54 (14) 31 (12)>3–6 months 28 (7) 6 (2)>6–9 months 26 (7) 6 (2)>9–12 months 8 (2) 6 (2)>12–15 months 14 (4) 2 (<1)>15–18 months 2 (<1) 1 (<1)>18–21 months 2 (<1) 7 (3)>21 months 3 (<1) 2 (<1)

b

Fig. 5 Incidence rate by cycle (a) and cumulative incidence (b) of new-onset diarrhea. Incidence rate is the number of events in a cycle divided by thesum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved

Incidence, n (%) Ixazomib (n=394)

Placebo (n=259)

0–3 months 37 (9) 23 (9)>3–6 months 12 (3) 5 (2)>6–9 months 12 (3) 6 (2)>9–12 months 4 (1) 2 (<1)>12–15 months 4 (1) 0>15–18 months 2 (<1) 2 (<1)>18–21 months 1 (<1) 1 (<1)>21 months 1 (<1) 0

Cum

ulat

ive

incid

ence

Months from date of first dose

00

2

4

6

8

10

12

14

16

18

20

5 10 15 20 25

Ixazomib: All grades

Placebo: All gradesPlacebo: Grade 2

Ixazomib: Grade 2Fig. 6 Cumulative incidence ofnew-onset PN. Only one patientin the ixazomib arm had grade 3PN (< 1%), and no patients ineither arm had grade 4 PN

302 Ann Hematol (2021) 100:297–302